Technology | May 07, 2013

Hospitals and their patients to benefit from reduced dose and faster exams


May 7, 2013 — UltraSPECT has announced its distribution agreement with PharmaLogic for the sale of UltraSPECT’s cardiac and bone imaging applications. The agreement will enable PharmaLogic to provide its hospitals and imaging centers with access to UltraSPECT’s Xpress line of products for lower radiation dose with no diminished image quality.

“UltraSPECT’s proprietary Wide-Beam Reconstruction technology enables our customers to achieve significant radiation dose reduction combined with greater patient comfort and higher throughput capacity,” said Steve Chilinski, president and CEO of PharmaLogic. “Even better, this technology can be easily implemented by retrofitting our customers’ existing facilities without the cost of new imaging camera systems."

Through the use of UltraSPECT’s innovative Wide-Beam Reconstruction (WBR) technology, the products in the company’s portfolio of solutions can provide two unique advantages. They significantly reduce the standard radiopharmaceutical dose requirements for cardiac and bone nuclear medicine imaging exams and/or cut the imaging procedure time in half while maintaining the image quality the facility is accustomed to. Many times they even enhance the image resolution. The company’s Xpress3.Cardiac solution provides benefits — enabling nuclear exams to be performed with 50 percent reduction in both dose and procedure time.

Both patients and technologists benefit from these improvements. With shorter exam times, patient comfort is increased with reduced risk of artifacts from patient movement. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many UltraSPECT users, the WBR technology results in higher patient throughput for enhanced equipment utilization, higher revenues and greater patient satisfaction and referrals.

UltraSPECT’s product line, utilizing WBR technology, is compatible with most major manufacturers’ nuclear medicine systems as well as clinical software packages.

For more information: www.ultraspect.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

February 1, 2024 — Banyan Software, a leading acquirer and permanent home for great software businesses, announces the ...

Time February 01, 2024
arrow
News | Radiation Therapy

January 19, 2024 — Treating tumors is a global health issue. In radiotherapy, radiation is used to destroy tumor cells ...

Time January 19, 2024
arrow
Subscribe Now